Fig 4.

Enhanced in vivo antitumor effect of bevacizumab (Bev) by nitric oxide donor S-nitrosated human serum albumin (SNO-HSA). (a) In C26 tumor-bearing mice (n = 4–9), SNO-HSA was injected i.v. through the tail vein, followed by Bev given i.p. Treatment was carried every 3 days for a total of six times. Results are for the following 18 days and are given as means ± SD. **P < 0.01 versus control. #P < 0.05 versus Bev alone. (b) At day 18, mice were killed, lungs were collected, and metastatic nodules on the surface of the lung were counted. Results are given as means ± SD. **P < 0.01 versus control.